{"id":"W2094345654","doi":"10.2337/dc13-0327","title":"Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Monoclonal antibody; Diabetes mellitus; Type 2 diabetes; Randomized controlled trial; Monoclonal; Antibody; Internal medicine; Immunology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001003249,0.0003621905,0.0008636853,0.0001094429,0.0001730339,0.00004934637,0.0005530217,0.0001791415,0.00001722965],"category_scores_gemma":[0.0007852528,0.0002798207,0.0002748215,0.0004228288,0.0001844256,0.0000101263,0.0003002018,0.000214893,0.00000790754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002901238,"about_ca_system_score_gemma":0.00008230827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004833352,"about_ca_topic_score_gemma":0.0001980562,"domain_scores_codex":[0.9967996,0.0008994824,0.0007554851,0.0006324319,0.0003375778,0.0005753977],"domain_scores_gemma":[0.9982955,0.00013284,0.0003813158,0.0008027558,0.0002982514,0.0000893722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.003580676,0.003511503,0.890604,0.0000719939,0.0005883874,0.000001892699,0.001831173,0.0001243594,0.09492236,0.000005484081,0.000706664,0.004051463],"study_design_scores_gemma":[0.6007236,0.004651591,0.217873,0.0002412082,0.0005612984,1.749579e-7,0.01153395,0.00029617,0.1593837,0.00009986456,0.003410827,0.001224552],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961845,0.0009224953,5.683443e-7,0.00005300311,0.0003181322,0.001699159,0.0002386698,0.00002192813,0.0005615301],"genre_scores_gemma":[0.998584,0.00008574956,0.00001008159,0.0001431716,0.0000810846,0.00008411564,0.0009023694,0.0000474489,0.00006194065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.672731,"threshold_uncertainty_score":0.9999654,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008577696229338936,"score_gpt":0.2799730497491972,"score_spread":0.2713953535198583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}